CD163 and cancer: M2 macrophages have a greater capacity for efferocytosis than M1 macrophages, which could explain why higher CD163 levels correlate with poor prognosis in some tumours [47], although, due to the plasticity of tumour-associated macrophages, high M2 macrophage infiltrates do not predict poor overall survival in all cancers [30].